Professor Minghui Duan: The Central Role of Genetic Testing in Hematologic Malignancies and Its Guidance for Personalized Therapy

Professor Minghui Duan: The Central Role of Genetic Testing in Hematologic Malignancies and Its Guidance for Personalized Therapy

From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin. The event brought together top experts from China and abroad to discuss key issues in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics spanned basic research, innovative drug development, precision medicine, and clinical translation. At the congress, Professor Minghui Duan from Peking Union Medical College Hospital delivered a compelling presentation titled “Key Considerations and Value of Genetic Testing in Hematologic Malignancies.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Duan elaborated on the critical role and latest advances of genetic testing in the diagnosis and treatment of blood cancers, offering valuable guidance for clinical practice.
Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres

Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres

From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress hosted by the Chinese Society of Clinical Oncology (CSCO) took place in Harbin. The conference brought together leading experts from China and abroad to discuss key topics in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics ranged from basic research and innovative drug development to precision medicine strategies and clinical translation. At the conference, Professor Yu Zhang from Southern Hospital of Southern Medical University delivered a compelling presentation titled “Optimizing the Diagnostic and Treatment Pathway for AML at Southern Hospital.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Zhang shared further insights into the hospital’s innovative approaches and practical experiences in managing acute myeloid leukemia (AML).
2025 BOC/BOA Kicks Off on July 4! Professor Jun Ma Invites You to Explore Global Frontiers in Hematologic Malignancies and Witness a New Era of Chinese Innovation

2025 BOC/BOA Kicks Off on July 4! Professor Jun Ma Invites You to Explore Global Frontiers in Hematologic Malignancies and Witness a New Era of Chinese Innovation

The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC), held in conjunction with Best of ASCO 2025 China (BOC/BOA), will take place from July 4–5 in the historic city of Nanjing. This prestigious event will gather leading oncology experts from across China and around the world to reflect on major clinical oncology advances in China over the past year and to present key takeaways from the recently concluded American Society of Clinical Oncology (ASCO) Annual Meeting.